This site is intended for
U.S.
Healthcare Professionals only.

For Patients
 
ionl-logo bms-logo
ionl-logo
Home > HOME > Immune Pathways > Immune Pathways

Immune Pathways

Click on one of the cells to explore.

 
Activating and inhibitory immune pathways diagram
 
 
 
 
 

The balance of activating and inhibitory pathways regulates antitumor immunity.

Click on one of the cells to explore.

Stroma

Click the links below for a closer look at individual stromal cell pathways.

Learn about:

Antigen Presentation

Click the links below for a closer look at individual antigen presenting cell pathways.

Learn about:

Effector Cells

Click the links below for a closer look at individual effector cell pathways.

Learn about:

Tumor Cells

Click the links below for a closer look at individual tumor cell pathways.

Learn about:

Immune Regulation

Click the links below for a closer look at individual immune regulatory cell pathways.

Learn about:

Select a pathway
  • Effector cells
  • Tumor cells
  • Antigen presentation
  • Immune regulation
  • Stroma

The balance of activating and inhibitory pathways regulates antitumor immunity.

Tap on a cell from the dropdown menu to explore.

Tap the links below for a closer look at individual effector cell pathways

Learn about:

Tap the links below for a closer look at individual tumor cell pathways

Learn about:

Tap the links below for a closer look at individual antigen presenting cell pathways

Learn about:

Tap the links below for a closer look at individual immune regulatory cell pathways

Learn about:

Tap the links below for a closer look at individual stromal cell pathways

Learn about:

Immuno-Oncology (I-O) aims to restore the body’s natural ability
to fight cancer

  • Various components of the immune system and the tumor microenvironment, including antigen-presenting cells (APCs), immune regulatory cells, stromal cells, and the tumor itself, regulate the ability of effector cells to eliminate tumors1-4
  • Ongoing I-O research at Bristol Myers Squibb (BMS) is exploring how targeting these components, either alone or in combination, may restore the body’s natural ability to fight cancer
  • Deep insight into tumor-intrinsic signaling and immune biology continues to inform and inspire discoveries—enabling BMS to develop novel therapies and combinations

Tap the links below to navigate to the individual pathway pages

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about our
current clinical trials

Learn more

REFERENCES–Immune pathways

1. Leung J, Suh W-K. The CD28-B7 family in anti-tumor immunity: emerging concepts in cancer immunotherapy. Immune Netw.
2014;14(6):265-276. 2. Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227-258. 3. Melero I, Berman DM, Aznar MA, Korman AJ, Pérez Gracia JL, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer. 2015;15(8):457-472. 4. Smyth MJ, Ngiow SF, Ribas A, Teng MWL. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol.
2016;13(3):143-158.